Humacyte Second Quarter 2022 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Humacyte, Inc. (HUMA) Tops Q2 EPS by 57c
August 12, 2022 7:05 AM EDTHumacyte, Inc. (NASDAQ: HUMA) reported Q2 EPS of $0.35, $0.57 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $235.4 thousand.
For earnings history and earnings-related data on Humacyte, Inc. (HUMA) click here.
... More